53BP1 is a novel regulator of angiogenesis in breast cancer

10Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In our previous study, we found that 53BP1 was a tumor suppressor and was associated with prognosis in breast cancer. However, little is known about its role in angiogenesis. In the present study, we aimed to reveal the role of 53BP1 in angiogenesis of breast cancer. With RNA interference and ectopic expression strategies to elucidate the detailed function of 53BP1 in angiogenesis, we observed that ectopic expression of 53BP1 inhibited cellular angiogenesis and 53BP1 RNA interference led to an increase in angiogenesis both in vitro and in vivo. In clinical breast cancer samples, 53BP1 was inversely correlated with CD31, MMP-2 and MMP-9 by immunohistochemistry analysis. Furthermore, we showed that the Akt pathway was involved in the antiangiogenesis function of 53BP1. Overall, our findings demonstrate that 53BP1 plays a vital role in inhibiting angiogenesis. These findings suggest that 53BP1 might provide a viable target therapy for breast cancer. © 2013 Japanese Cancer Association.

Cite

CITATION STYLE

APA

Li, X., Kong, X., Wang, Y., & Yang, Q. (2013). 53BP1 is a novel regulator of angiogenesis in breast cancer. Cancer Science, 104(11), 1420–1426. https://doi.org/10.1111/cas.12247

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free